course of trades, page-4

When it comes to biotechs CCE certainly did look good... just a poor commercial outcome. Perhaps they should have just out licensed the technology.

I play around with biotechs but never fall in love with them... just not worth it. Have a plan as to when you will exit e.g. If they fail this clinical trial or if they fail to out license any compounds by this date etc... the exit strategy will save you many times from a long drawn out affair... not only capital losses but time spent on research when you should really be looking for new opportunities.

You run out of money before you'll ever run out of opportunities!